Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Autor:	Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Vatsa S; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Lindell KA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Demato A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Blood cancer discovery [Blood Cancer Discov] 2022 Mar 01; Vol. 3 (2), pp. 136-153.
DOI:	10.1158/2643-3230.BCD-21-0181
Abstrakt:	Chimeric antigen receptor (CAR) T cells induce impressive responses in patients with hematologic malignancies but can also trigger cytokine release syndrome (CRS), a systemic toxicity caused by activated CAR T cells and innate immune cells. Although IFNγ production serves as a potency assay for CAR T cells, its biologic role in conferring responses in hematologic malignancies is not established. Here we show that pharmacologic blockade or genetic knockout of IFNγ reduced immune checkpoint protein expression with no detrimental effect on antitumor efficacy against hematologic malignancies in vitro or in vivo. Furthermore, IFNγ blockade reduced macrophage activation to a greater extent than currently used cytokine antagonists in immune cells from healthy donors and serum from patients with CAR T-cell-treated lymphoma who developed CRS. Collectively, these data show that IFNγ is not required for CAR T-cell efficacy against hematologic malignancies, and blocking IFNγ could simultaneously mitigate cytokine-related toxicities while preserving persistence and antitumor efficacy. Significance: Blocking IFNγ in CAR T cells does not impair their cytotoxicity against hematologic tumor cells and paradoxically enhances their proliferation and reduces macrophage-mediated cytokines and chemokines associated with CRS. These findings suggest that IFNγ blockade may improve CAR T-cell function while reducing treatment-related toxicity in hematologic malignancies. See related content by McNerney et al., p. 90 (17). This article is highlighted in the In This Issue feature, p. 85. (©2021 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu